Vaccination

A technique of vaccination, vaccination, applied in the field of elderly and immunocompromised human patients, which can solve the problem of unidentified immunological links

Inactive Publication Date: 2017-08-29
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF24 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No immunological link to protection identified so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccination
  • Vaccination
  • Vaccination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0054] Preferred embodiments of the invention include:

[0055] - an immunogenic (e.g. vaccine) composition comprising the VZV gE antigen or derivative thereof truncated to remove the carboxy-terminal anchor region in combination with an adjuvant comprising QS21, 3D- MPL and liposomes comprising cholesterol for use in a method for protecting or preventing herpes zoster (HZ) in individuals 70 years of age or older for at least 5 years and / or postherpetic neuralgia.

[0056] - an immunogenic (e.g. vaccine) composition comprising the VZV gE antigen or derivative thereof truncated to remove the carboxy-terminal anchor region in combination with an adjuvant comprising QS21, 3D- MPL and liposomes comprising cholesterol, the composition for use in a method for protecting or preventing herpes zoster (HZ) and / or in individuals greater than 70 years of age for at least 5 years or postherpetic neuralgia.

[0057] - an immunogenic (e.g. vaccine) composition comprising the VZV gE antige...

Embodiment 1

[0070] Example 1 - Vaccine Efficacy Against HZ in Adults 50 Years and Older

[0071] Example 1 describes the results of a Phase III, randomized, observer-blinded, placebo-controlled, multicentre, clinical vaccination trial that demonstrated Prophylactic efficacy, safety, and immunogenicity of a candidate HZ vaccine, GSK Biologicals' VZV gE / AS01B vaccine, when administered intramuscularly on a 2-month schedule.

[0072] The study population included men and women without severe immunocompromised conditions in the age ranges of 50-59 years (YOA), 60-69 YOA, 70-79 YOA, and >80 YOA. The 70–79 YOA layers and ≥80 YOA layers were pooled for primary analysis. Assigning approximately 20-25% of the ≥70 YOA group to those with ≥80 YOA ensures that this particularly susceptible population is adequately represented.

[0073] The candidate HZ vaccine tested in this trial was the adjuvanted recombinant VZV gE vaccine as described herein. Saline solution was included in this study as a neg...

Embodiment 2

[0097] Example 2 - Vaccine efficacy against HZ in immunocompromised adults

[0098] Example 2 describes a Phase III, randomized, observer-blinded, placebo-controlled, multicenter, clinical trial that demonstrated Prophylactic efficacy, safety and immunogenicity of an adjuvanted VZV gE vaccine candidate when administered intramuscularly in humans, here adult autologous hematopoietic stem cell transplantation (HCT) recipients.

[0099] The adjuvanted VZV gE vaccine candidate tested in this trial was the same vaccine candidate tested in the trial described in Example 1. Since the candidate vaccine is a subunit vaccine, there is no risk that the vaccine itself will cause varicella or HZ, a potential concern following vaccination with live VZV.

[0100] figure 2 The study design is depicted.

[0101] The primary aim of the clinical trial was to evaluate the vaccine efficacy (VE) for the prevention of HZ in autologous HCT recipients 18 years and older. Additional objectives incl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to compositions for use in and methods for protecting against HZ resulting in an unprecedented efficacy and duration of protection with a minimal number of vaccine administrations.

Description

technical field [0001] The present invention relates to a method of inducing long-lasting protection against herpes zoster or postherpetic neuralgia with high potency and preventing herpes zoster or postherpetic neuralgia, especially in elderly and immunocompromised human patients. Background technique [0002] Herpes Zoster (HZ), also known as shingles, is a common and often debilitating disease that occurs mainly in elderly or immunocompromised individuals. HZ is caused by symptomatic reactivation of latent varicella zoster virus (VZV) in dorsal roots and cranial ganglia. The virus is often acquired as chickenpox in childhood. [0003] The only vaccine currently available with proven efficacy against HZ or post-herpetic neuralgia is a live attenuated vaccine of the VZV OKA strain as Zostavax TM market. In all populations (≥60 YOA), Zostavax TM reduced the incidence of HZ by 51.3% (p-value < 0.001), although its effectiveness decreased with the age of the vaccinee. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/25A61K39/39A61P31/22
CPCA61K39/12A61K39/39A61K2039/545A61K2039/55A61K2039/55555A61K2039/55572A61K2039/55577C12N2710/16734A61P25/02A61P25/04A61P29/02A61P31/22A61K39/25C12N7/00
Inventor T.C.海涅曼E.G.C.莱登特N.P.F.勒克勒尼耶
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap